– USA, MA – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing led by Novo Holdings A/S along with Access Biotechnology and founding investor Atlas Venture that seeded the company in 2017.…
Rappta Therapeutics strengthens its Board along with raising €9m Series A financing co-led by Novartis Venture Fund and Novo Holdings
– FINLAND, Helsinki – Rappta Therapeutics, focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A, today announced the closing of a €9 million Series A financing co-led by Novartis Venture Fund and Novo Holdings with participation from Advent Life Sciences and a family office.…